Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study

References

• Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010;103:139–47
   PubMed Web of Science ®Google Scholar
• Al Arouj M, Assaad-Khalil S, Buse J et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895–902
   PubMed Web of Science ®Google Scholar
• Salti I, Benard E, Detournay B et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306–11
   PubMed Web of Science ®Google Scholar
• Hui E, Bravis V, Hassanein M et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:c3053
   PubMed Web of Science ®Google Scholar
• Barnett AH, Cradock S, Fisher M et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121–9
   PubMed Web of Science ®Google Scholar
• Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169–76
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245–54
   PubMed Web of Science ®Google Scholar
• Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193–8
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197–202
   PubMedGoogle Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–72
   PubMed Web of Science ®Google Scholar
• Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714–27
   PubMed Web of Science ®Google Scholar
• Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55:S20–S27
   PubMed Web of Science ®Google Scholar
• van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735–41
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Krahenbuhl S et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case–control analysis. Diabetes Care 2008;31:2086–91
   PubMed Web of Science ®Google Scholar
• Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45–53
   PubMed Web of Science ®Google Scholar
• Cesur M, Corapcioglu D, Gursoy A et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007;75:141–7
   PubMed Web of Science ®Google Scholar
• Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63:1446–50
   PubMed Web of Science ®Google Scholar
• The Glimepiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421–2
   Google Scholar
• Belkhadir J, El Ghomari H, Klocker N et al. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292–5
   PubMed Web of Science ®Google Scholar
• Sari R, Balci MK, Akbas SH, et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004;30:169–77
   PubMed Web of Science ®Google Scholar
• Uysal AR, Erdogan MF, Sahin G et al. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan. Diabetes Care 1998;21:2033–4
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535–42
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications 2009;23:376–9
   PubMed Web of Science ®Google Scholar
• Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28:426–9
   PubMed Web of Science ®Google Scholar
• Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563–84
   PubMed Web of Science ®Google Scholar
• Tessier D, Dawson K, Tetrault JP et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994;11:974–80
   PubMed Web of Science ®Google Scholar
• Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDMpatients treated with oral hypoglycemic agents. Diabetes Care 1989;12:203–8
   PubMed Web of Science ®Google Scholar
• Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948–61
   PubMed Web of Science ®Google Scholar